Tags : Eligible

Roche Reports Launch of First CDx VENTANA PD-L1 (SP142) Assay

Shots: The launch of VENTANA PD-L1 (SP142) follows the US FDA’s approval in Mar’2019, as the first CDx assay involved in identifying triple-negative breast cancer (TNBC) patients associated with 3 proteins estrogen receptor, progesterone receptor and HER2/neu eligible for treatment with Tecentriq combination The assay is developed for the enhancement of visual contrast of tumor-infiltrating […]Read More